A NOVEL METHOD FOR THE SIMULTANEOUS DETERMINATION OF OLANZAPINE AND ESCITALOPRAM IN SALIVA BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

Year 2024, , 505 - 512, 23.10.2024

Aysun Dinçel , Selin Şamil Elif Damla Gök Topak

https://doi.org/10.55262/fabadeczacilik.1536799

Abstract

Monitoring of the drug levels can be very important for efficient drug treatment. For this purpose, studies on drug analysis from various biological fluids, especially plasma are carried out in analytical chemistry. For many drugs, determination of saliva drug concentration can be used alternatively for drug level monitoring. Patients with cognitive dysfunction have difficulty in maintaining normal living standards and adapting to society. Individuals with such disorders need to be treated with an appropriate medication regimen. Generally, treatment is provided with orally and the most commonly used antipsychotic drugs are olanzapine (OLZ) and escitalopram (ESC). Measurement of saliva drug concentration of OLZ and ESC can be useful for treatment of diseases. In this study, it is aimed to develop a novel HPLC method that will allow OLZ and ESC to simultaneously determination in artificial saliva. The separation was achieved on XBridge, C18 column with diode array detector (DAD) (240 nm) and isocratic elution of acetonitrile and phosphate buffer mixture (20 mM NaH2PO4, pH 4.6) 35:65 (v/v) containing mobile phase at a flow rate of 0.9 mL/min. Drug extraction from artificial saliva was applied by using methanol and acetonitrile (1:1; v/v) mixture. The recoveries were found in the range of 97.508 % and 104.49 % (mean) for OLZ and ESC respectively from artificial saliva.

Keywords

Olanzapine, Escitalopram, Saliva, HPLC

Supporting Institution

Tubitak

Project Number

2209-1919B012216080

References

• Teichert, J., Rowe, J.B., Ersche. K.D., Skandali. N., Sacher. J., Aigner, A. (2020). Determination of Atomoxetine or Escitalopram in human plasma by HPLC. Applications in Neuroscience Research Studies. International Journal of Clinical Pharmacology and Therapeutics, 58(8), 426-438. doi:10.5414/CP203705.